125 related articles for article (PubMed ID: 8310677)
1. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
Teh LC
Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
[TBL] [Abstract][Full Text] [Related]
2. Large-scale gel filtration chromatography for the production of a solvent/detergent-treated high-purity factor VIII concentrate.
Dengler T; Stöcker U; Kellner S; Fürst G
Vox Sang; 1990; 58(4):257-63. PubMed ID: 1697997
[TBL] [Abstract][Full Text] [Related]
3. Large-scale preparation of a highly purified solvent-detergent treated factor VIII concentrate.
Myers R; Wickerhauser M; Charamella L; Simon L; Nummy W; Brodniewicz-Proba T
Vox Sang; 1991; 60(3):141-7. PubMed ID: 1907414
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
5. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
Branović K; Gebauer B; Trescec A; Benko B
Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
[TBL] [Abstract][Full Text] [Related]
6. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
[TBL] [Abstract][Full Text] [Related]
7. [Development and characterization of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Bhattacharya P; Jorquera JI
Sangre (Barc); 1996 Apr; 41(2):125-30. PubMed ID: 9045352
[TBL] [Abstract][Full Text] [Related]
8. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
9. Isolation of the factor VIII-von Willebrand factor complex directly from plasma by gel filtration.
Kaersgaard P; Barington KA
J Chromatogr B Biomed Sci Appl; 1998 Sep; 715(2):357-67. PubMed ID: 9792522
[TBL] [Abstract][Full Text] [Related]
10. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
[TBL] [Abstract][Full Text] [Related]
11. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Schwinn H; Smith A; Wolter D
Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
[TBL] [Abstract][Full Text] [Related]
12. Removal/neutralization of hepatitis A virus during manufacture of high purity, solvent/detergent factor VIII concentrate.
Lemon SM; Murphy PC; Smith A; Zou J; Hammon J; Robinson S; Horowitz B
J Med Virol; 1994 May; 43(1):44-9. PubMed ID: 8083647
[TBL] [Abstract][Full Text] [Related]
13. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
14. Treatment of type III von Willebrand's disease with solvent/detergent-treated factor VIII concentrates.
Gazengel C; Fischer AM; Schlegel N; Rothschild C; Torchet MF; Dautzenberg MD; Aujard Y
Nouv Rev Fr Hematol (1978); 1988; 30(4):225-7. PubMed ID: 3143100
[TBL] [Abstract][Full Text] [Related]
15. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
[TBL] [Abstract][Full Text] [Related]
16. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.
Raut S; Di Giambattista M; Bevan SA; Hubbard AR; Barrowcliffe TW; Laub R
Thromb Haemost; 1998 Oct; 80(4):624-31. PubMed ID: 9798982
[TBL] [Abstract][Full Text] [Related]
17. Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.
Hughes C; Thomas KB; Schiff P; Herrington RW; Polacsek EE; McGrath KM
Transfusion; 1988; 28(6):566-70. PubMed ID: 3143170
[TBL] [Abstract][Full Text] [Related]
18. High-purity factor VIII concentrates produced without using monoclonal antibodies.
Mannucci PM; Gringeri A; Cattaneo M
Ric Clin Lab; 1990; 20(4):227-37. PubMed ID: 2127470
[TBL] [Abstract][Full Text] [Related]
19. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
[TBL] [Abstract][Full Text] [Related]
20. Direct capture of plasma factor VIII:C by ion exchange chromatography.
Teh LC; Froger M
Vox Sang; 1994; 67(1):8-13. PubMed ID: 7975461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
